GEN Exclusives

More »

GEN News Highlights

More »
Jul 16, 2014

Sun Pharma Nabs Injectable Drug CMO Pharmalucence

  • A subsidiary of Sun Pharmaceutical Industries has acquired New England-based firm Pharmalucence, which manufactures human injectable pharmaceuticals. Sun says Pharmalucence has sterile injectable capacity in the U.S., supported by strong R&D capabilities.

    Pharmalucence says it provides contract and private label formulation development and manufacturing services of noncytotoxic human injectables in either liquid or lyophilized form. According to the company's website, Pharmalucence has a 70,000 sq. ft. facility it claims to be New England's first CMO to use fully automated and isolated aseptic technology in support of customer needs ranging from small clinical fills to full commercial scale production.

    This has been an eventful year for the Indian generics manufacturer as in April Sun Pharma picked up fellow generics firm Ranbaxy Laboratories for $4 billion, with the aim of creating the world’s fifth-largest generic drug company. Also, in May, Sun Pharma closed down its Detroit facility run by Caraco Pharmaceutical Laboratories, of which Sun Pharma is a majority owner. The FDA shut down this facility in 2009 for failing to meet cGMP requirements; the facility reopened in August of 2012.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »